Patents by Inventor Richard Alan Earl

Richard Alan Earl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20170050966
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: April 23, 2015
    Publication date: February 23, 2017
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher Matthew Liu, Guohua Liang, Matthew F. Baevsky, Richard Alan Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
    Patent number: 5990132
    Abstract: Compounds of Formula (I) have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man where subnormal levels of this neurochemical are found, such as in Alzheimer's disease, and other conditions involving learning and cognition.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: November 23, 1999
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Christopher Allan Teleha, Wendell Wilkie Wilkerson, Richard Alan Earl
  • Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
    Patent number: 5750528
    Abstract: Compounds which block neuronal M-channels are useful for treating conditions involving neurotransmitter deficiencies, traumatic brain injury, or the depressive phase of bipolar disorder. Compounds can be evaluated for utility in treating these conditions by determining whether they are capable of blocking neuronal M-channels.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: May 12, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Barry Stephen Brown, Simon Piers Aiken, Robert Zaczek, Paul Richard Hartig, Christopher Allan Teleha, Wendell Wilkie Wilkerson, Richard Alan Earl